Generic Pharmaceuticals Company Investment Opportunity in Hyderabad, India
- We are a generic pharmaceutical R&D company that is based in Hyderabad, India.
- Developing 3 NCEs that are potential "super generic" versions of widely-used drugs - omeprazole, naproxen and aspirin.
- USA and Canada are our primary markets and we will also bring our products to India once they gain respectable sales figures.
- Planning to develop these NCEs through the least-expensive 505 (b) (2) NDA route, which is the most economical and fastest route to drug development and approval by the US FDA.
- Currently in the pre-clinical stage and will get all the regulatory approvals as per the requirement.
- We have already obtained a US patent for 2 NCEs (i. e. , Super generic versions of naproxen and aspirin) and we are in the process of filing a patent application for the other NCE (i. e. , a potential super generic omeprazole).
- With an initial investment of Rs. 4.4 Crores (~600,000 USD), we will take up omeprazole prodrug as our first candidate for development through 505 (b) (2) NDA route.
- Once we reach the manufacturing stage, we may outsource all the manufacturing of these products.
We intend to develop potentially "super generic" versions of widely used generic drugs omeprazole, naproxen and aspirin.
1 week, 2 days agoHead Marketing, Pharmaceuticals, Hyderabad, Individual Investor / Buyer connected with this business
1 week, 6 days agoPartner, Logistics, Pune, Corporate Investor / Buyer accepted business proposal
Earlier than 15 daysCoordinator, Investments & Finance, Vilnius, Corporate Investor / Buyer accepted business proposal